Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

China Aortic Infection and Graft Infection Study: An Ambispective Cohort (CAIGIS)

29. September 2026 aktualisiert von: Qing Miao, Shanghai Zhongshan Hospital

Clinical Characteristics, Treatment Strategies, and Prognostic Factors of Infectious Arterial Diseases: A Single-Center, Real-World, Ambispective Observational Cohort Study

Vascular infections are uncommon but severe infections involving the arterial wall, vascular grafts, or endografts, and their diagnosis and management remain challenging. The CAIGIS Cohort is an ambispective observational cohort established at Zhongshan Hospital, Fudan University, to create an integrated clinical research platform and biobank for patients with suspected or confirmed vascular infections.

The primary research focus is the diagnosis and characterization of causative pathogens. Conventional microbiological methods and emerging molecular diagnostic technologies will be systematically evaluated, with particular emphasis on blood-based pathogen detection as a form of liquid biopsy and its diagnostic value compared with local tissue or operative specimens. Serial blood samples and tissue specimens, when available, will also be used to investigate biomarkers associated with treatment response and clinical outcomes.

Another major focus is the role of molecular imaging, particularly 18F-FDG PET/CT, in the diagnosis and longitudinal assessment of vascular infections. The study will evaluate its diagnostic performance, its added value in patients with inconclusive conventional imaging, and the potential significance of changes in metabolic activity during follow-up for assessing treatment response, residual infection, recurrence, and prognosis.

The cohort will further support nested translational studies addressing specific pathogen- and disease-related questions. These include longitudinal characterization of microbial communities in patients with vascular-enteric fistulas; evaluation of the clinical significance and invasive potential of Candida species; investigation of the clinical and biological characteristics of mycobacterial vascular infections; and exploration of pathogen-host interactions within infected vascular tissues.

By integrating longitudinal clinical data, microbiological results, molecular diagnostics, PET/CT findings, treatment information, outcomes, and biospecimens, the cohort aims to improve etiological diagnosis, disease stratification, treatment monitoring, prognostic assessment, and understanding of the pathogenesis of vascular infections.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

Vascular infections encompass a heterogeneous group of severe infectious diseases involving the arterial wall, vascular grafts, or endografts, including infectious aortitis, infected arterial aneurysms, vascular graft and endograft infections, and fistula-associated vascular infections. These conditions are associated with substantial morbidity and mortality and remain challenging with respect to etiological diagnosis, assessment of disease activity, therapeutic decision-making, and prediction of recurrence and long-term outcomes.

The CAIGIS Cohort is an ambispective observational cohort established at Zhongshan Hospital, Fudan University. The study is designed as a longitudinal clinical research platform integrating standardized clinical data, microbiological investigations, molecular diagnostics, imaging, treatment information, outcome assessment, and longitudinal biospecimen collection. Patients with suspected or confirmed vascular infections will be included and followed longitudinally. In addition to characterization of the overall disease spectrum, the cohort will serve as a platform for multiple nested diagnostic, prognostic, microbiological, imaging, and translational studies.

Etiological diagnosis and evaluation of diagnostic technologies constitute a major focus of the cohort. Conventional microbiological methods, including blood culture, operative specimen culture, histopathology, and pathogen-specific serological testing, will be evaluated together with emerging molecular diagnostic technologies. Particular attention will be given to blood-based pathogen detection as a form of liquid biopsy, including metagenomic and targeted sequencing approaches where available. Diagnostic yield, incremental diagnostic value, time to etiological diagnosis, concordance between blood and local-site specimens, and the clinical impact of different diagnostic strategies will be investigated. Operative tissue and prosthetic material, when available, will provide an important reference for evaluating blood-based diagnostic approaches.

The cohort will also investigate dynamic biomarkers for disease activity and prognosis. Serial blood samples obtained during diagnosis, treatment, and follow-up may be used to characterize changes in pathogen-derived signals and host-response biomarkers. Their associations with microbiological clearance, treatment response, persistent infection, recurrence, reoperation, and mortality will be explored. The long-term objective is to develop integrated diagnostic and prognostic models combining clinical, microbiological, molecular, imaging, and host-response information.

A further research focus is the role of 18F-FDG PET/CT and other imaging modalities in both diagnosis and longitudinal monitoring. The diagnostic performance and incremental value of PET/CT, particularly in patients with inconclusive conventional imaging, will be evaluated. Where serial PET/CT examinations are clinically available, changes in metabolic activity and imaging patterns will be studied in relation to treatment response, residual infection, recurrence, and prognosis. Quantitative and semi-quantitative imaging parameters may be integrated with microbiological and biomarker data to investigate whether multimodal assessment can improve disease classification and therapeutic monitoring.

Fistula-associated vascular infection, particularly vascular-enteric fistula-associated infection, represents another key area of investigation. These patients often demonstrate complex polymicrobial patterns and may undergo substantial changes in microbial composition during antimicrobial treatment, surgery, and postoperative recovery. Serial blood, operative tissue, fistula-adjacent specimens, and other clinically obtained samples may therefore be used to characterize the longitudinal dynamics of microbial communities, distinguish vascular pathogens from enteric-source organisms, and explore the relationship between microbial composition, fistula status, treatment strategy, and clinical outcome.

The cohort will also support pathogen-specific translational studies. For Candida species, research will focus on distinguishing colonization or contamination from clinically significant invasive vascular infection and identifying microbiological, imaging, host, and clinical features associated with invasive disease and adverse outcomes. For mycobacterial vascular infections, including infections caused by Mycobacterium tuberculosis and nontuberculous mycobacteria, studies will investigate clinical characteristics, diagnostic features, microbial determinants, host susceptibility, and potential mechanisms underlying vascular tropism and persistent infection.

In patients undergoing surgery, infected vascular tissues and prosthetic materials may additionally be used to investigate in situ pathogen-host interactions. These studies may examine the spatial distribution of pathogens within infected tissue, local inflammatory and immune responses, tissue injury, and the relationship between microbial localization and pathological phenotype. Depending on specimen availability and individual nested study protocols, approaches may include microbiological, histopathological, molecular, genomic, transcriptomic, and spatial analyses.

Through the integration of clinical phenotyping, longitudinal biospecimen collection, pathogen-oriented diagnostics, liquid biopsy, molecular imaging, prognostic biomarkers, and translational investigation, the CAIGIS Cohort aims to establish a comprehensive research infrastructure for vascular infections. The overarching goal is to improve etiological diagnosis, disease stratification, treatment monitoring, prognostic assessment, and mechanistic understanding of these complex infections.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

2000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Shanghai, China, 200032
        • Rekrutierung
        • Zhongshan Hospital, Fudan University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population consists of consecutive adult patients evaluated or treated at Zhongshan Hospital, Fudan University, for suspected or confirmed vascular infections involving the native arterial wall, vascular grafts, or endografts. The cohort includes infectious aortitis, infected arterial aneurysms, vascular graft or endograft infections, and fistula-associated vascular infections. The ambispective design includes retrospectively identified patients with adequate clinical records and prospectively enrolled patients undergoing longitudinal follow-up. Clinical, microbiological, imaging, treatment, and outcome data will be collected, and biospecimens will be retained when available. Final diagnostic classification will be determined by multidisciplinary adjudication integrating clinical presentation, microbiological and molecular findings, imaging, pathology, operative findings, and longitudinal clinical course.

Beschreibung

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. Patients with suspected or confirmed vascular infection involving the native arterial wall, vascular graft, or endograft, including but not limited to infectious aortitis, infected arterial aneurysm, vascular graft or endograft infection, and fistula-associated vascular infection.
  3. Patients evaluated or treated at Zhongshan Hospital, Fudan University, with sufficient clinical information to allow diagnostic adjudication and outcome assessment.
  4. For the prospective cohort, willingness to participate and provide informed consent when required.
  5. For the retrospective cohort, availability of relevant clinical records meeting the requirements approved by the institutional ethics committee.

Exclusion Criteria:

  1. Isolated superficial surgical-site infection without evidence of involvement of the arterial wall, vascular graft, or endograft.
  2. Insufficient clinical data to permit diagnostic adjudication or longitudinal outcome assessment.
  3. Refusal to participate in the prospective component when informed consent is required.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Patients With Vascular Infections

Patients with suspected or confirmed vascular infections, including infectious aortitis, infected arterial aneurysms, vascular graft or endograft infections, and fistula-associated vascular infections. Clinical, microbiological, molecular diagnostic, imaging, treatment, outcome, and biospecimen data will be collected longitudinally to support diagnostic, prognostic, and translational studies.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sustained Cure Rate One Year After Discontinuation of Antimicrobial Therapy
Zeitfenster: 1 year after discontinuation of antimicrobial therapy

Proportion of participants who remain alive and free from persistent or recurrent vascular infection for 1 year after discontinuation of antimicrobial therapy, without reinitiation of antimicrobial treatment for the index vascular infection or unplanned infection-related surgical or endovascular intervention.

1 year after discontinuation of antimicrobial therapy
Five-Year All-Cause Mortality
Zeitfenster: 5 years after the index diagnosis

Proportion of participants who die from any cause within 5 years after the index diagnosis of vascular infection.

5 years after the index diagnosis

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of Patients Requiring Lifelong Suppressive Antimicrobial Therapy
Zeitfenster: Up to 2 years after diagnosis

Proportion of participants requiring indefinite or lifelong suppressive antimicrobial therapy because complete eradication of vascular infection is not considered achievable. The proportion will be assessed separately among patients managed conservatively and those undergoing surgical or endovascular treatment.

Up to 2 years after diagnosis
Five-Year Infection-Related Mortality
Zeitfenster: Up to 5 years after the index diagnosis

Percentage of participants who die from causes directly or indirectly attributable to the index vascular infection within 5 years after the index diagnosis. Infection-related death will be determined by multidisciplinary clinical adjudication based on the clinical course, microbiological findings, imaging, operative findings, and documented cause of death.

Up to 5 years after the index diagnosis

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incremental Diagnostic Yield of Individual Diagnostic Technologies
Zeitfenster: Within 90 days after the index diagnosis

Proportion of participants in whom an additional etiological diagnosis is established by a specific diagnostic modality beyond conventional microbiological evaluation. Incremental diagnostic yield will be assessed separately for blood-based molecular diagnostics, including liquid biopsy approaches, serological testing, molecular testing of local or operative specimens, and other advanced diagnostic methods where available.

Within 90 days after the index diagnosis
Rate of Diagnostic Test-Related Changes in Clinical Management
Zeitfenster: From enrollment to 90 days after the index diagnosis

Rate of Diagnostic Test-Related Changes in Clinical Management

From enrollment to 90 days after the index diagnosis

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. November 2036

Studienabschluss (Geschätzt)

1. November 2041

Studienanmeldedaten

Zuerst eingereicht

22. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. September 2026

Zuerst gepostet (Tatsächlich)

29. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CAIGIS-202611

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data that underlie the results reported in peer-reviewed publications may be shared upon reasonable request. Data sharing will be subject to approval by the study investigators and relevant institutional or ethics committees, and will comply with applicable privacy, data protection, and regulatory requirements. Data containing potentially identifiable, genomic, or other sensitive information may be subject to additional restrictions.

IPD-Sharing-Zeitrahmen

Beginning 12 months after publication of the main study results and available for 5 years.

IPD-Sharing-Zugriffskriterien

Researchers may submit a scientifically sound proposal to the principal investigator. Requests will be reviewed based on scientific merit, feasibility, participant privacy, ethical approval, and applicable institutional and regulatory requirements. Approved researchers may be required to sign a data use agreement before access is granted.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .